Global Stem Cell Market Expected to Reach $270.5 Billion

The global stem cell market is expected to reach US 270.5 Billion by 2025, while increasing at a compound annual growth rate of 13.8% during the period from 2017 to 2025. All this comes from a report published by Transparency Market Research. From a global perspective, North America accounts for …

5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH

The stars are aligning for several biotech stocks. Thirty-five billion stars in fact. That huge number in dollars represents the potential annual spending needed to treat one of the biggest and growing problems facing the healthcare sector today. We’re talking about NASH. Most often occurring in obese or glucose-intolerant people, …

Gene editing of dogs offers hope for treating human muscular dystrophy

Fighting fire with fire, researchers working with dogs have fixed a genetic glitch that causes Duchenne muscular dystrophy (DMD) by further damaging the DNA. The unusual approach, using the genome editor CRISPR, allowed a mutated gene to again make a key muscle protein. The feat—achieved for the first time in …

First CRISPR clinical trial backed by U.S. companies launches

The first clinical trial of CRISPR-Cas9 sponsored by U.S. companies has launched, testing the genome-editing technique in patients with the blood disorder beta thalassemia, according to an announcement posted Friday on the U.S. clinical trials website. The Phase 1/2 clinical trial, co-sponsored by Vertex Pharmaceuticals and using an experimental treatment …

3 Hot Trends Warren Buffett Is Missing Out On — But You Don’t Have To

You have an investing advantage over Warren Buffett. No, seriously, you really do. Buffett has admitted that he regrets not buying Google parent Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) and Amazon.com years ago. And he’s only been a big buyer of Apple stock in the past few years. Apple gained more …

Sarepta shares rocket 40% on promising early results for DMD gene therapy

Sarepta Therapeutics Inc. shares skyrocketed 37.8% in Tuesday trade after the company released promising early results from a gene therapy program being developed for the rare degenerative disease Duchenne muscular dystrophy. Tuesday marked the stock’s second-largest percentage gain in over 20 years. Its largest-ever percentage gain came in September 2016, …

Are These Red-Hot NASH Stocks Still a Buy?

Over the last two weeks, shares of Madrigal Pharmaceuticals (NASDAQ: MDGL), Galmed Pharmaceuticals (NASDAQ: GLMD), and Viking Therapeutics (NASDAQ: VKTX) have more than doubled in value. The reason? Each of these companies is developing a drug for a deadly form of fatty liver disease known as non-alcoholic steatohepatitis (NASH). The …

Tech workers are paying $7,000 to freeze their stem cells in hope of extending life

Start-up investor Li Jiang just turned 30, and now he can’t stop thinking about his own mortality. For Jiang, who’s based in San Francisco, living longer isn’t just about eating healthy and exercising regularly. Last month, he cryogenically froze his stem cells, in the hopes of someday injecting them back …